

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The results of the Phase III MDS-005 study evaluating the efficacy and safety of lenalidomide in red blood cell transfusion-dependent patients with low- to intermediate-risk myelodysplastic syndromes (MDS) without a del(5q) abnormality demonstrated _____ among patients who received lenalidomide compared to placebo.

 - A significant improvement in transfusion independence
 - No improvement in transfusion independence
 - Consistency with response rates in the MDS-002 trial
 - Both a and c
- Hypomethylating agents increase the expression of PD-1 and PD-L1 genes in MDS, and this increase enhances the activity of immune checkpoint inhibitors.

 - True
 - False
- _____ is a novel agent that inhibits the transforming growth factor (TGF)-beta superfamily that has shown potential in the treatment of low-risk MDS.

 - Venetoclax (ABT-199)
 - Luspatercept (ACE-536)
 - Sotatercept (ACE-011)
 - All of the above
 - Both b and c
- Patients with MDS who develop resistance to hypomethylating agents might have mutations in which of the following genes?

 - IDH1
 - IDH2
 - FLT3
 - All of the above
- A retrospective analysis of patients with MDS who discontinued therapy with hypomethylating agents after achieving a partial or complete response demonstrated prolonged progression-free survival after cessation of therapy.

 - True
 - False
- Which of the following statements is true regarding the use of 5-azacitidine in the treatment of MDS?

 - It is a hypomethylating agent
 - It does not prolong overall survival
 - It is commonly associated with injection site reactions
 - All of the above
 - Both a and c
- Among patients with MDS, those with _____ have an increased likelihood of benefitting from treatment with lenalidomide.

 - Del(5q)
 - Platelet counts that are <100,000
 - Both a and b
- Imetelstat, a _____, has shown promising activity in preliminary studies for patients with lower-risk MDS.

 - Bcl-2 inhibitor
 - PD-1/PD-L1 inhibitor
 - Telomerase inhibitor
- Which of the following statements is true about iron chelation therapy (ICT) in MDS?

 - Results from randomized trials strongly support the clinical effectiveness of ICT in patients with MDS.
 - No randomized trials support the clinical effectiveness of ICT in patients with MDS.

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

10. Mutations in which of the following genes predict poor outcomes after allogeneic hematopoietic stem cell transplantation for patients with MDS?
- a. p53
 - b. DNMT3A
 - c. Both a and b